Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 13/20 | 0.74 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.71 |
| ▸ | PIM1 | P11309 | 3/20 | 0.63 |
| ▸ | PIM2 | Q9P1W9 | 3/20 | 0.63 |
| ▸ | PPARG | P37231 | 2/20 | 0.60 |
| ▸ | IGF1R | P08069 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.59 |
| ▸ | RXRA | P19793 | 1/20 | 0.59 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2002766 | 1.00 | HPGD (0.74) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL29668090 | 1.00 | HPGD (0.74) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL2002770 | 1.00 | HPGD (0.74) | HPGDCISD1PIM1PIM2PPARG | |
| Hydrochloric Acid SCHEMBL5169138 | 0.99 | HPGD (0.72) | HPGDCISD1PIM1PIM2PPARG | |
| Hydrochloric Acid SCHEMBL5169128 | 0.98 | HPGD (0.71) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL4743937 | 0.92 | HPGD (0.64) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL4743932 | 0.92 | HPGD (0.64) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL2002768 | 0.88 | HPGD (0.59) | HPGDCISD1PIM1PIM2PPARG | |
| Hydrochloric Acid SCHEMBL5169131 | 0.87 | PPARG (0.59) | HPGDCISD1PIM1PIM2PPARG | |
| SCHEMBL20302565 | 0.86 | HPGD (0.59) | HPGDCISD1PIM1PIM2PTPN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1663170-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2015-06-24 | — | — | EP | claimed |
| US-9060941-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2015-06-23 | — | — | US | claimed |
| US-8668931-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2014-03-11 | — | — | US | claimed |
| US-20130266647-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ACTAVIS HOLDCO US, INC. | 2013-10-10 | — | — | US | claimed |
| US-8470368-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | WATSON PHARMACEUTICALS, INC. (US) | 2013-06-25 | — | — | US | claimed |
| US-20110262538-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS, INC. (US) | 2011-10-27 | — | — | US | claimed |
| US-7959946-B2 | Sustained release; hypoglycemic agents; synergistic mixture | WATSON PHARMACEUTICALS, INC. (US) | 2011-06-14 | — | — | US | claimed |
| EP-1863445-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS INC (US) | 2016-05-11 | — | — | EP | disclosed |
| US-9078885-B2 | Respiratory disease treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2015-07-14 | — | — | US | disclosed |
| EP-1663170-B1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2015-06-24 | — | — | EP | disclosed |
| US-9060941-B2 | Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20150072001-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS INC (US) | 2015-03-12 | — | — | US | disclosed |
| US-20140248357-A1 | Respiratory Disease Treatment | PULMAGEN THERAPEUTICS (INFLAMMATION) LIMITED (GB) | 2014-09-04 | — | — | US | disclosed |
| EP-1863445-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | Watson Pharmaceuticals, Inc. (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006107528-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | WATSON PHARMACEUTICALS, INC. (US) | 2006-10-12 | — | — | WO | disclosed |
| EP-1663170-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | Andrx Labs Llc (US) | 2006-06-07 | — | — | EP | disclosed |
| US-20050249809-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | WATSON PHARMACEUTICALS, INC. | 2005-11-10 | — | — | US | disclosed |
| US-20050226928-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS, INC. | 2005-10-13 | — | — | US | disclosed |
| WO-2005039540-A1 | NOVEL PHARMACEUTICAL FORMULATION CONTAINING A BIGUANIDE AND A THIAZOLIDINEDIONE DERIVATIVE | ANDRX LABS LLC (US) | 2005-05-06 | — | — | WO | disclosed |
| US-20040161462-A1 | Novel pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative | ACTAVIS HOLDCO US, INC. | 2004-08-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140248357-A1 | Respiratory Disease Treatment | IL5, PPARD, SLC5A1 | HPGD 2189/4885CISD1 2890/4885PIM1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.